Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Collegium Pharmaceutical
COLL
5
Enerpac Tool
EPAC
US Stock MarketDetailed Quotes
BCRX BioCryst Pharmaceuticals
- 11.030
- +2.100+23.52%
Close May 5 16:00 ET
- 11.070
- +0.040+0.36%
Post 20:01 ET
2.31BMarket Cap-25.65P/E (TTM)
11.110High9.590Low26.30MVolume9.795Open8.930Pre Close273.93MTurnover13.48%Turnover RatioLossP/E (Static)209.21MShares11.11052wk High-4.85P/B2.15BFloat Cap5.34052wk Low--Dividend TTM195.16MShs Float37.250Historical High--Div YieldTTM17.02%Amplitude0.600Historical Low10.414Avg Price1Lot Size
Market Insights
Discussing
Trade war escalates: What’s next for Chinese stocks?
🎙️Discussion 1. China-EU EV negotiations kick off recently. How do you think the negotiations will impact the performance of related stocks
Moo Earnings
Feb 17 19:21
Alibaba Q4 FY2024 Earnings Preview: Predict & Win Big! 🚀
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
BioCryst Pharmaceuticals Stock Forum
--Q1 2025 ORLADEYO net revenue of $134.2 million (+51 percent y-o-y)--
--Full year 2025 ORLADEYO revenue guidance increased to $580 million to $600 million--
--Company now expects to be profitable for full year 2025, a year ahead of schedule--
--Company pays down $75 million of debt; saves approximately $23.5 million over life of loan--
dip = buy！
Can This Rare Disease Drug Eliminate HAE Attacks in Children? Clinical Trial Says Yes
BioCryst Pharmaceuticals Inc - Increases Wholesale Acquisition Cost for Orladeyo to $44,484.33 per 28-Day Pack
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release
7. Remember, some stocks may get pumped WITHOUT any catalyst
8. NEVER be a blind follower.
LASTLY, If y...
$Aethlon Medical (AEMD.US)$
$BioCryst Pharmaceuticals (BCRX.US)$
$CureVac (CVAC.US)$
$GeoVax Labs (GOVX.US)$
$Inovio Pharmaceuticals (INO.US)$
$Nanoviricides (NNVC.US)$
$China SXT Pharmaceuticals (SXTC.US)$
$Virax Biolabs (VRAX.US)$
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours)
7. Remember, ...
No comment yet